readthroughSign in
Nov 16, 2026Quarterly update

Apnimed's Oxnimbi NDA stays under FDA review with February 2027 goal date

The company reported CHEST 2026 data presentations and commercial launch preparations while its $351.8 million cash balance is expected to fund operations into the second quarter of 2028.

Apnimed announced third quarter 2026 financial results on November 16, 2026, reporting that its NDA for AD109, proposed proprietary name Oxnimbi, for the treatment of adults with obstructive sleep apnea remains under FDA review, with a PDUFA goal date of February 28, 20271.

The company said it kept building out commercial readiness, covering market access and payer engagement, hiring a commercial team and go-to-market planning, and manufacturing and distribution work, to prepare for a possible U.S. launch of Oxnimbi if the FDA approves it1.

At the American College of Chest Physicians' CHEST 2026 Annual Meeting, Apnimed said it presented five abstracts: three covering Phase 3 AD109 data, including two late-breakers and one on patient-reported outcomes, plus two real-world studies on the burden of OSA1. The company noted the meeting also included a CHEST-led panel discussion on results from the Phase 3 SynAIRgy and LunAIRo trials and how they might apply to OSA management1.

On financing, Apnimed said it finished an upsized initial public offering in August 2026 that brought in about $198.9 million in net proceeds1. As of September 30, 2026, the company reported $351.8 million in cash and cash equivalents, which it said positions it to support commercial readiness and a potential U.S. launch of Oxnimbi if the FDA approves the drug1. Separately, Apnimed stated this cash position is expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 20281.

For the quarter, Apnimed reported a net loss of $29.5 million, compared with a net loss of $10.9 million for the same quarter in 20251.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.